викинг

Damaged nerve cells repaired in laboratory 04 Aug 2009 Researchers at the University of California in San Diego have discovered a way to repair the damaged caused to nerve cells in spinal cord injury. For the first time scientists appear to have successfully repaired broken nerve connections in laboratory models of spinal cord injury. If the technique is developed further it may be applicable to other neurological conditions such as multiple sclerosis (MS). The research, published this week in the journal Nature Neuroscience, is the first time such an experiment has been successful in re-establishing broken nerve connections, Despite these promising findings, the resulting connections were not able to transmit messages from one end of the nerve to the other. This is a major hurdle to overcome before a treatment can be considered and is the subject of ongoing research. Dr Doug Brown, Research Manager at the MS Society said, "This is an exciting piece of early research that holds promise for people with neurological conditions such as MS. "It is, however, worth remembering that this research is at the very earliest stages of development. "The next step is to find ways of overcoming technical difficulties that the researchers experienced and to determine how useful this technique will really be for people with long-term neurological conditions."

Основная проблема, которою может сздать миток. - проблемы с сердцем, При дозе более 140 мг/м2, Это печально!

Тайсабри, т.к. майкрософт и Тайсон произносятся именно так.

Шура! Может быть это и не мой вопрос, но следует говорть тайсабри!

К стати, а почему у нас до сих пор не утвердили TYSABRI?

Это известно всем плохишам! Тонешь сам - помоги другому!

К сожлению это полная фигня!. Ох уж эти горе-изобретатели!

Гнрмания страна бльшая. А куда летите?

Начните с копаксона!

Рона! У нас по-прежнему любое дело надо "подталкивать".

А я тоже знаю людей, которые сидят дома икоторыми никто из врачей не интересуется!

Хрошо вам в Питере! В Москве нет ничего подобного ! Никто ниечего не предлагает!

А проверяли его?

MS Trial Alert: Sites in Ohio, Texas, and Washington Recruiting for a Small Study of Autologous ("Self") Hematopoietic Stem Cell Transplant Underway Summary: Investigators at three sites in the United States (Columbus, Ohio; Houston, Texas; and Seattle, Washington) are conducting an open-label study to test the safety and effectiveness of high-dose immunosuppressive therapy (chemotherapy) followed by autologous (cells from patient’s own blood) hematopoietic stem cell transplant in 30 people with relapsing-remitting* or progressive-relapsing* MS. The investigators will consider participants who are not patients in their treatment centers, but please keep in mind that several visits and a hospital stay are necessary for this trial (travel expenses will be reimbursed). This study also is known as the HALT-MS study, and is funded by the National Institute of Allergy and Infectious Disease of the National Institutes of Health. Rationale: Autologous hematopoietic stem cell transplantation uses the patients’ own blood or bone marrow stem cells. The procedure generally involves first collecting a person’s cells that are capable of regenerating into new immune cells. These “stem cells” are stored, and then the rest of his or her immune cells are destroyed by a chemotherapy regimen. After chemotherapy, the stored stem cells are reintroduced by injection. Eventually they grow and repopulate the body with new immune cells. The hope is that the new immune cells will no longer attack nerve fiber-insulating myelin or other brain tissue (the targets of the immune attack in MS), having learned to be “immune tolerant.” This attempt to “reboot” the immune system is strictly investigational for MS, although it has obtained FDA approval for other diseases, such as cancer. The procedure is not without risk, one of these being serious, potentially life-threatening infections due to the weakened state of the immune system before it is fully restored. Adjunct medications such as antibiotics and antivirals are being provided in this study to reduce this risk. Eligibility and Details: Participants must be between the ages of 18 and 60, and diagnosed with relapsing-remitting or progressive-relapsing MS less than 15 years ago. They will have active disease, despite previous treatment with disease-modifying therapies. At the beginning of the study, participants will undergo a number of screening and baseline procedures, including a physical exam, blood collection, neurology exams and questionnaires, and MRI scans. After transplantation, participants will remain in the hospital for observation and will be monitored for infections. Following discharge from the hospital, eight study visits will occur over five years. Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please contact the site nearest you or visit http://www.halt-ms.org/index.html. Download a brochure that discusses issues to think about when considering enrolling in an MS clinical trial (PDF). *Relapsing-Remitting

MS Trial Alert: Sites in Ohio, Texas, and Washington Recruiting for a Small Study of Autologous ("Self") Hematopoietic Stem Cell Transplant Underway

Mitoxantrone, known by the brand name Novantrone or DHAD, is approved by the US Food and Drug Administration for the treatment of aggressive relapsing-remitting MS. Previous studies have linked treatment with mitoxantrone with an increased risk of acute leukemia. According to those studies, acute leukemia occurred in 0.07 percent to 0.25 percent of MS patients taking mitoxantrone. However, in a retrospective study of 2854 Italian patients with MS receiving the drug, Martinelli's group found that 21 -- or 0.74 percent -- developed acute leukemia, 8 of whom died. Acute leukemia developed an average of 37 months after the start of mitoxantrone and an average of 18 months after the end of treatment Перевод: Mitoxantrone, известный фирменным знаком Novantrone или DHAD, одобрен американским Управлением по контролю за продуктами и лекарствами для обработки агрессивной переводящей вторичное впадение MS. Предыдущие исследования связали обработку с mitoxantrone с увеличенным риском острой лейкемии. Согласно тем исследованиям, острая лейкемия произошла в 0.07 процентах с 0.25 процентами пациентов MS, берущих mitoxantrone. Однако, в ретроспективном исследовании 2854 итальянских пациентов с MS, получающей препарат, группа Martinelli's нашла, что 21 - или 0.74 процента - заболел острой лейкемией, 8 из которых умерли. Острая лейкемия развивала среднее число 37 месяцев после начала mitoxantrone и среднего числа 18 месяцев после конца обработки

Трудно жить до нашей эры Жизнь - одно головотяпство Слабый пол страдал без меры Женщин угоняли в рабство На дорогах неспокойно Нет церквей, спасенья, веры В мире не было законов Вот лишь краткие примеры: Знаем государство Спарта, Как одно не из плохих, Но вот день Восьмого Марта не справлял никто у них Греки были строгих нравов не пускали женский пол Дальше всем известных храмов, Где творили произвол Феодалы сплошь дурили, Кто нарядней тот и лих Ну а дамам говорили, что дерутся из-за них Время шло менялись нравы Господа рабы война Кто богаче те и правы Вот такие времена То, что нравы изменились Не исправило беды Но однажды появились Наших классиков труды Маркс и Энгельс были цепки, Как хороший драматург Им попалась Клара Цеткин Вместе с Розой Люксембург Революция в Чикаго Стачка Лейстерских ткачей Всюду сплошь страдали дамы От буржуйских палачей Маркс раскрыл противоречья И нашел причину зла Вот тогда на ваши плечи манна с неба потекла Коммунизма ждали малость В этом не было вреда Было все, но оказалось Не для всех и не всегда Жизнь сюрпризы преподносит Миром правит эгоизм Комунизма не дождались Вновь настал капитализм Не грусти весной о лете А вино по кружкам лей Нету праздника на свете Неизменней и милей Мы довольны есть причины Было вам за что страдать Праздник каждому мужчине Прость повод чтоб поддать. викинг

Feb 26, 2009 Positive Results Published of First of Two Phase 3 Clinical Trials of Fampridine-SR Walking speed improved significantly in a phase 3 clinical trial of 301 people with all types of MS taking oral Fampridine-SR (Acorda Therapeutics, Inc.), a drug designed to provide symptomatic relief by compensating for lost nerve conduction. Fampridine-SR is a sustained-release formula of 4-aminopyridine, which temporarily enhances nerve signaling by blocking tiny pores, or potassium channels, on the surface of nerve fibers. A paper describing the study, by Dr. Andrew Goodman (University of Rochester) and colleagues, is published in the February 28, 2009 issue of The Lancet (2009 373;732-738). Results from a later, second Phase 3 study, announced in 2008, confirmed Fampridine’s benefits reported here. In early February 2009, Acorda announced that it had applied to the FDA for marketing approval of Fampridine for multiple sclerosis. Background: Problems with gait (difficulty in walking) are among the most common mobility limitations experienced by people with MS. Fampridine-SR is a sustained-release formula of 4-aminopyridine, which blocks tiny pores, or potassium channels, on the surface of nerve fibers. This blocking ability may improve the conduction of nerve signals in nerve fibers whose insulating myelin coating has been damaged by MS. The first studies of this potassium-blocking approach in people with MS were supported by the National MS Society. The Study: A total of 301 people with all types of MS participated at 33 sites in the U.S. and Canada. Participants were randomly divided such that 224 were on active treatment and 72 were on inactive placebo over 14 weeks. Participants were permitted to remain on other medications during the trial, establishing the potential of the drug as a symptomatic management strategy that could be used along with their regular medications and disease-modifying therapies. Results: Thirty-five percent of those on active therapy, versus only 8 percent of the placebo group, experienced significant improvements in walking speed. The walking speed for those who responded to therapy improved an average of 25.2% (in the timed 25-foot walk), compared to only 4.7 percent in the placebo group, and the improvement was maintained over the 14 weeks of therapy. Improvement was also noted in the “MS Walking Scale 12,” a measure designed to assess how meaningful the improvement was for individuals; in this study, those who responded to the drug reported feeling less disabled in daily activities requiring mobility. Other positive outcomes included increased leg strength in those on active treatment, even in some individuals whose walking speed did not improve. Common adverse events (side effects) experienced more often by those on active treatment included back pain, dizziness, insomnia, fatigue, nausea and balance disorder. Serious adverse events that led to discontinuation of the drug included one case of anxiety and one seizure in a person who developed sepsis from a urinary tract infection. There were no deaths during the treatment phase of the study, but one person died five weeks after the last treatment visit of heart disease, which was deemed by investigators to be unrelated to the therapy. Results from a later, second phase 3 study, announced in 2008, confirmed the benefits seen in this trial. The company announced that it had applied to the FDA for marketing approval of Fampridine in early February 2009. Comment: “The phase 3 results on Fampridine suggest that this drug has the potential to temporarily restore function and make a real difference to some people’s quality of life,” said John Richert, MD, Executive Vice President of Research & Clinical Programs for the National MS Society. “If the FDA agrees that Fampridine is safe and effective, it would bring a welcome symptomatic therapy that has potential utility for a large number of people with different types of MS.” As the authors noted in the paper, “We could not identify any factor that predisposes patients with multiple sclerosis to respond to fampridine on a particular measure.” Further study and clinical practice may help determine the extent to which the drug may impact other functions not measured in the clinical trials, and provide hints as to which patients are most likely to respond. Back to Top

Young Smokers Increase Risk for Multiple Sclerosis Libraries Medical News Keywords NEUROLOGY, JOURNAL NEUROLOGY, NEUROLOGY, AMERICAN ACADEMY OF NEUROLOGY, AAN, MULTIPLE SCLEROSIS, SMOKERS, SMOKING, MS, EARLY SMOKERS, LATE SMOKERS Contact Information Available for logged-in reporters only Description People who start smoking before age 17 may increase their risk for developing multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology’s 61st Annual Meeting in Seattle, April 25 to May 2, 2009. Newswise — People who start smoking before age 17 may increase their risk for developing multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology’s 61st Annual Meeting in Seattle, April 25 to May 2, 2009. The study involved 87 people with MS who were among more than 30,000 people in a larger study. The people with MS were divided into three groups: non-smokers, early smokers (smokers who began before age 17), and late smokers (those who started smoking at 17 or older), and matched by age, gender, and race to 435 people without MS. Early smokers were 2.7 times more likely to develop MS than nonsmokers. Late smokers did not have an increased risk for the disease. More than 32 percent of the MS patients were early smokers, compared to 19 percent of the people without MS. “Studies show that environmental factors play a prominent role in multiple sclerosis,” said study author Joseph Finkelstein, MD, PhD, of Johns Hopkins University School of Medicine, in Baltimore, MD, which conducted the study in collaboration with Veterans Affairs MS Center for Excellence. “Early smoking is an environmental factor that can be avoided.” The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as multiple sclerosis, restless legs syndrome, Alzheimer’s disease, narcolepsy, and stroke. For more information about the American Academy of Neurology, visit www.aan.com . The AAN 61st Annual Meeting, the world’s largest gathering of neurology professionals, takes place April 25 to May 2, 2009, in Seattle. Visit www.aan.com/am for more information. Editor’s Note: Study authors are available for interviews. Please contact Jenine Anderson, janderson@aan.com or Jay Mac Bride, jmacbride@aan.com. To access 2009 AAN Annual Meeting abstracts available February 25, 2009, visit http://www.aan.com/go/science/abstracts. Late-breaking abstracts will be featured in press release at the 2009 AAN Annual Meeting in Seattle.

http://www.nationalmssociety.org/research/...ex.aspx?nid=758

Feb 04, 2009 Promise: 2010 Nervous System Repair Teams Meet, Plan Next Steps Toward Restoring Nerve Function in People with MS Over 70 members of the four international teams funded through the National MS Society’s Promise: 2010 Campaign met in New York City in January to share progress, forge new collaborations, and plan future steps to speed efforts toward clinical trials of therapies to protect and reverse neurological damage in people with multiple sclerosis. With the Society’s pledged funding of $15.6 million for five years, the teams have been conducting a broad range of studies aimed at protecting and reversing neurological damage – from basic molecular studies to planning clinical trials. Leading these four teams are Peter A. Calabresi, MD (Johns Hopkins University), Charles ffrench-Constant, PhD, FRCP (University of Edinburgh and University of Cambridge, UK), Gavin Giovannoni, MBBCh, PhD (Queen Mary University of London, UK) and Ian D. Duncan, BVMS, PhD, FRCPath (University of Wisconsin Madison). Each team reported impressive progress, and clinical trials of potential nerve-protecting agents are already underway. Read details of the progress reported at the meeting in the “Research Now” section of the Society’s Momentum magazine (PDF) Searching for New Targets and Therapies: The search for repair strategies begins with efforts to find the therapeutic targets that end up under study in clinical trials in people with MS. The teams reported exciting search results related to their use of advanced tools to identify molecules that facilitate myelin repair or protect nerve integrity. Several candidates have been identified and are ready to be taken to the next stage of clinical development. Progress was also reported in identifying cell populations that may be key to strategies involving transplanting cells to stimulate repair. In addition, team members discussed strategies for testing the potential of existing drugs that may be re-purposed for MS. Tracking Success: Finding noninvasive methods of pinpointing nerve fiber damage – and repair – is crucial to preventing disease progression and for determining whether future repair strategies are working. Teams are testing many types of novel imaging techniques, and are also identifying “biomarkers,” such as the presence of specific proteins in the blood or spinal fluid, that would provide a snapshot of a person’s disease status and the health of their tissues. Clinical Trials: The ultimate goal of the Society’s repair initiative is to translate these findings into clinical trials of agents that can rebuild damaged tissues in people with MS and/or protect against further injury. The teams are in the process of creating new clinical trial designs that will allow the use of fewer participants and permit faster determinations about the possible benefits of new therapies. Ancillary to the repair initiative, Dr. Giovannoni reported progress on two ongoing studies focused on neuroprotection in which his team is participating. One involves lamotrigine, a drug used in epilepsy, which is being tested in a phase 2 study to see if it can slow brain tissue loss in people with secondary-progressive MS. Results are expected to be available this year. The other is a large multicenter study is investigating whether the active compound in cannabis, THC (Tetrahydrocannabinol, which has shown benefit in pre-clinical studies), can slow MS progression. Results are expected in late 2011. In addition, two of the teams are about to launch new, small-scale clinical trials, also with separate funding. One will investigate the safety of treatment with bone marrow (“mesenchymal”) stem cells; the other will attempt injections of neural stem cells. (Both trials are fully enrolled and awaiting further funding and approvals.) It is not clear yet whether either of these cell types will actually serve as replacement cells to restore brain tissue. Research in animal models suggests that these cells may create an environment that stimulates repair by resident cells. More research, which is ongoing, will help bring clarity to these and other questions. As Dr. Giovannoni commented, “We’re still learning how to do [cell therapy] trials, but we’ve got to start somewhere, and we will learn by doing them, even if their results are initially negative.” Team members discussed further steps that could speed efforts toward clinical trials of repair strategies and the need for guidelines for future trials that will result in the most informative outcomes. “We’re more than halfway there,” said John Richert, MD, Executive Vice President of the National MS Society’s Research & Clinical Programs Department in his address to workshop participants. “Thanks in large part to your work, we now have tremendous leads for strategies to protect people with MS from nervous system damage and to even reverse that damage.”

Genetic study shows direct link between vitamin D and MS susceptibility ‘gene’ 05 Feb 2009 Scientists have found evidence that a direct interaction between vitamin D and a common genetic variant alters the risk of developing multiple sclerosis (MS). The research published in the journal PLoS Genetics suggests that vitamin D deficiency during pregnancy and the early years may increase the risk of the offspring developing MS later in life. The causes of MS are unclear, but it has become evident that both environmental and genetic factors play a role. Previous studies have shown that populations from Northern Europe have an increased MS risk if they live in areas receiving less sunshine. This supports a direct link between deficiency in vitamin D, produced in the body through the action of sunlight, and increased risk of developing the condition. Now, in a study funded by the UK's MS Society, the MS Society of Canada, the Wellcome Trust and the Medical Research Council, researchers at the University of Oxford and the University of British Columbia have established a direct relationship between a gene variant known as DRB1*1501 and vitamin D. The research has been welcomed by Simon Gillespie, Chief Executive of the MS Society (UK). "These remarkable results tie together leading theories about the environment, genes and MS but they are only part of the jigsaw," he said. "This discovery opens up new avenues of MS research and future experiments will help put the pieces together." While one in 1,000 people in the UK are likely to develop MS, this number rises to around one in 300 amongst those carrying a single copy of the variant and one in 100 of those carrying two copies. The researchers found that proteins activated by vitamin D in the body bind to a particular DNA sequence lying next to the DRB1*1501 variant, in effect switching the gene on. “In people with the DRB1 variant associated with MS, it seems that vitamin D may play a critical role,” said co-author Dr Julian Knight. “If too little of the vitamin is available, the gene may not function properly." "We have known for a long time that genes and environment determine MS risk," said Professor George Ebers, University of Oxford. "Here we show that the main environmental risk candidate – vitamin D – and the main gene region are directly linked and interact." "Our study implies that taking vitamin D supplements during pregnancy and the early years may reduce the risk of a child developing MS in later life," said lead author Dr Sreeram Ramagopalan. "Vitamin D is a safe and relatively cheap supplement with substantial potential health benefits. There is accumulating evidence that it can reduce the risk of developing cancer and offer protection from other autoimmune diseases." Дмитрий - Перевод: Генетическое исследование показывает прямую связь между витамином D и восприимчивостью MS 'ген' 05 февраля 2009 Ученые нашли свидетельство, что прямое взаимодействие между витамином D и общим генетическим вариантом изменяет риск развивающегося рассеянного склероза (MS). Исследование издало в журнале, Генетика PLoS предполагает, что дефицит витамина D во время беременности и первые годы может увеличить риск потомства, развивающего MS позже в жизни. Причины MS неясны, но стало очевидно, что и экологические и генетические факторы играют роль. Предыдущие исследования показали, что у поселений из Северной Европы есть увеличенный риск MS, если они живут в областях, получающих меньше света. Это поддерживает прямую связь между дефицитом в витамине D, произведенном в теле через действие солнечного света, и увеличенным риском развития условия. Теперь, в исследовании, финансируемом Обществом MS Великобритании, Общество MS Канады, Доверия Wellcome и Медицинского Совета Исследования, исследователей в Университете Оксфорда и Университете Британской Колумбии установило прямые отношения между генным вариантом, известным как DRB1*1501 и витамином D. Исследование приветствовалось Саймоном Gillespie, Руководителем Общества MS (Великобритания). "Эти замечательные результаты связывают ведущие теории об окружающей среде, генах и MS, но они - только часть мозаики," сказал он. "Это открытие открывает новые авеню исследования MS, и будущие эксперименты помогут соединить части." В то время как один в 1 000 человек в Великобритании, вероятно, разовьют MS, эти повышения числа к приблизительно каждому 300-ому среди тех, которые несут единственную копию варианта и каждого 100-ого из тех, которые несут две копии. Исследователи нашли, что белки, активизированные витамином D в теле, связывают со специфической последовательностью ДНК, лежащей рядом с вариантом DRB1*1501, в действительности включая ген. “В людях с вариантом DRB1, связанным с MS, кажется, что витамин D может играть критическую роль,” сказал Рыцарь соавтора доктора Julian. “Если слишком мало витамина доступно, ген, возможно, не функционирует должным образом." "Мы знали в течение долгого времени, что гены и окружающая среда определяют риск MS," сказали Профессор Джордж Ebers, Университет Оксфорда. "Здесь мы показываем, что главный экологический кандидат риска – витамин D – и главная генная область непосредственно связан и взаимодействует." "Наше исследование подразумевает, что взятие приложений витамина D во время беременности и первые годы может уменьшить риск ребенка, развивающего MS в будущем," сказал ведущий автор доктор Sreeram Ramagopalan. "Витамин D является безопасным и относительно дешевым приложением с существенной потенциальной пользой для здоровья. Там накапливает свидетельство, что это может уменьшить риск развивающегося рака и предложить защиту от других аутоиммунных болезней."

Stem Cell transplant trial results - The Lancet Neurology 30 Jan 2009 The Lancet Neurology has today published the results of a trial involving stem cell transplantation in people with relapsing remitting multiple sclerosis (MS). The results of the Chicago study of around 20 people show that the treatment halted progression of disability and could potentially reverse the damage caused in MS. Dr Doug Brown, Research Manager at the MS Society, said: “These are very encouraging results and it's exciting to see that in this trial not only is progression of disability halted, but damage appears to be reversed. “Stem cells are showing more and more potential in the treatment of MS and the challenge we now face is proving their effectiveness in trials involving large numbers of people.”

Oral pill shows promise 23 Jan 2009 Early results released today from a two-year phase III trial of an oral therapy for relapsing remitting multiple sclerosis (MS) called Cladribine have shown that the pill can reduce relapse rates by up to 58 per cent. Cladribine is the first potential oral treatment for MS to complete a final phase clinical trial. It is expected that developers Merck Serono will apply for the registration of this therapy in mid-2009, which is one of the final steps required before the drug is considered for availability in the UK. Dr Lee Dunster, Head of Research at the MS Society said: "This drug is the first oral pill to reach this stage in testing and the reported outcomes are positive. "An alternative to regular injections will be welcome relief for people living with MS and we look forward to an effective and safe oral pill being available."

Диагноз сей - куда мрачнее Чем скарлатина и понос Ведь нет болезни сволочнее Чем злой рассеянный склероз